Vanda Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of clinical-stage product candidates for central nervous system disorders worldwide. Its product portfolio includes iloperidone, a compound for the treatment of schizophrenia and bipolar disorder; VEC-162, a compound for the treatment of insomnia and depression; and VSF-173, a compound for the treatment of excessive daytime sleepiness. The company is evaluating iloperidone in a Phase III trial for schizophrenia; and VEC-162 in a Phase III trial for insomnia. Vanda Pharmaceuticals was founded by Mihael H. Polymeropoulos in 2002. The company is headquartered in Rockville, Maryland.